A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants with End‐Stage Kidney Disease on Hemodialysis
The Journal of Clinical Pharmacology · 2026-04 · 66 (4)
DOI: 10.1002/jcph.70195 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 24.04.2026. Verfasst von Caroline Mohrmann und 11 weiteren Autor:innen. Beteiligte Einrichtung: Amgen Inc., Thousand Oaks, CA, USA. Hauptthemen laut MEDLINE: Renal Dialysis, Kidney Failure, Chronic. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Amgen Inc., Amgen.
Abstract (Originalsprache)
The effect of end‐stage kidney disease (ESKD) and hemodialysis (HD) on avacopan exposure is unknown. This Phase 1 study evaluated the pharmacokinetics (PK) and safety of avacopan and its active metabolite M1 in healthy participants and participants with ESKD requiring HD following a single 30‐mg oral dose administered with food. Healthy participants (N = 6) received one dose of avacopan, while participants with ESKD (N = 7) received a single 30‐mg oral dose during each treatment period 18 days apart: once 4 h before HD and once on a non‐HD day. PK parameters included area under the plasma concentration–time curve from time 0 to last quantifiable concentration (AUC last ), AUC from time 0–48 h (AUC 0–48 ), and maximum concentration (C max ). Comparisons were based on geometric least squares mean (GLSM) ratios with 90% confidence intervals. Relative to healthy participants, avacopan exposure on the non‐HD day in participants with ESKD was similar, with GLSM ratios of 0.862 for AUC 0–48 , 1.12 for AUC last , and 1.03 for C max . Corresponding M1 exposures were lower in participants with ESKD, with GLSM ratios ranging from 0.639 to 0.658. Within the ESKD group, avacopan exposure on the HD day was lower than on the non‐HD day (GLSM ratios: 0.699–0.914), while M1 exposure was comparable between periods. Adverse events were mild to moderate and consistent with the known safety profile of avacopan. These findings indicate that ESKD or HD has no clinically meaningful impact on avacopan or M1 exposure, and dose adjustment may not be necessary in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Amgen Inc., Thousand Oaks, CA, USA.
- Fortrea Inc., Durham, NC, USA.
- Orlando Clinical Research Center, Orlando, FL, USA.
- Floridian Clinical Research, Miami Lakes, FL, USA.
- Amgen Inc., South San Francisco, CA, USA.
ORCID-Profile: Caroline Mohrmann, Rajneet K Oberoi, Vijay V Upreti
Förderung
- Amgen Inc.
- Amgen
Zitieren
APA
Mohrmann, C., Oberoi, R. K., Flach, S. D., Marbury, T. C., Hernandez, P., Gokhale, M., MacElrevey, C. R., Sampson, C., Amouzadeh, H., Hudson, K., Upreti, V. V., & Ward, J. A. (2026). A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants with End‐Stage Kidney Disease on Hemodialysis. The Journal of Clinical Pharmacology, 66(4). https://doi.org/10.1002/jcph.70195
Vancouver
Mohrmann C, Oberoi RK, Flach SD, Marbury TC, Hernandez P, Gokhale M, et al. A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants with End‐Stage Kidney Disease on Hemodialysis. The Journal of Clinical Pharmacology. 2026;66(4). doi:10.1002/jcph.70195
BibTeX
@article{Mohrmann2026,
author = {Mohrmann, Caroline and Oberoi, Rajneet K and Flach, Stephen D and Marbury, Thomas C and Hernandez, Pedro and Gokhale, Manoj and MacElrevey, Celeste R and Sampson, Caitlin and Amouzadeh, Hamid and Hudson, Krischan and Upreti, Vijay V and Ward, Jessica A},
title = {A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants with End‐Stage Kidney Disease on Hemodialysis},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
volume = {66},
number = {4},
doi = {10.1002/jcph.70195}
}
EUVIMED